“Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison”, J of Skin, vol. 10, no. 2, p. s738, Mar. 2026, doi: 10.25251/0bwr4a20.